Menthol for Improving Movement and Sleep in Parkinson's Disease Patients
ConditionParkinson's Disease
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age30-80
SponsorTaipei Medical University Hospital
About this trial
Parkinson's disease (PD) is a progressive neurological disorder characterized by both motor and non-motor symptoms due to the degeneration of dopamine-producing neurons. There is currently no cure. Menthol, a natural compound that activates TRPM8 receptors, has shown neuroprotective and motor function benefits in preclinical PD models. In mice, distal limb immersion in menthol improved dopamine neuron survival and motor performance. Similar menthol-based interventions improved outcomes in a stroke model and a clinical trial with stroke patients. This study investigates whether topical menthol can offer therapeutic benefits for individuals with PD.
Eligibility criteria
Qualifiers
aged between 30 and 80 years (inclusive);
diagnosed with idiopathic PD based on the Brain Bank criteria of the UK Parkinson's Disease Society less than 3 years;
Hoehn and Yahr stages 1-3 and currently receiving treatment; experiencing sleep disorders with a Pittsburgh Sleep Quality Index (PSQI) > 5;
has signed the informed consent form approved by the Institutional Review Board and dated accordingly;
Disqualifiers
menthol allergy;
pregnant and breastfeeding women;
diagnosed with secondary and atypical PD;
patients with conditions such as uremia, cirrhosis, congestive heart failure with pulmonary edema, coagulation disorders, epilepsy, alcoholism, drug abuse, or
Trial design
Treatments tested in this trial
- Menthol gloves and socks
- Placebo gloves and socks
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
Taipei Medical University Hospital
Lead sponsor
China Medical University, Taiwan
Collaborator
Source ClinicalTrials.gov